Round 4: J&J Vs MSAC... again

Posted 3 February 2025 PM

Johnson & Johnson Innovative Medicine has made a fourth trip back to MSAC for its CAR T therapy Carvykti, seeking a less arduous funding model than the Committee's recommendation for drip-feed payments over four years.

After two years of tense negotiations the multiple myeloma (MM) treatment was recommended by MSAC last April but came with a gruelling pay-for-performance (PfP) agreement that would see the company paid by installment over four years for patients whose disease had not progressed. This, MSAC said, was based on its review of clinical data which showed some patients saw their myeloma return within four years of treatment.

To see the whole article, please login